COVID-19: 2 Pharma firms’ report hopeful as vaccine shows minimal side effects ─Study

*Experts say vaccine shows minimal side effects and loss of smell should be an official symptom

Alexander Davis | ConsumerConnect

As the global community awaits the production and distribution of safe and effective vaccines against the novel Coronavirus disease (COVID-19), Moderna and Regeneron are two pharmaceutical firms reporting encouraging news about their Coronavirus (COVID-19) vaccine efforts.

ConsumerConnect learnt a fresh study has indicated that Moderna’s vaccine candidate is about as effective in older adults as it is with young people.

The vaccine also showed minimal side effects, according to researchers.

Regeneron also reported that its COVID-19 antibody cocktail reduced levels of the virus in patients with the illness and eased symptoms in people who had milder forms of the virus.

The company reportedly plans to step up efforts to win approval for the drug from regulators.

While researchers say loss of smell should be an official symptom, they maintain that symptoms of the Coronavirus can vary widely, but one of them is nearly universal.

They say four out of five people experiencing a recent loss of smell and/or taste tested positive for COVID-19 antibodies.

Of those testing positive, 40 percent did not have cough or fever, according to a new study published in PLOS Medicine by researchers from University College London.

The findings are important for policymakers around the world because most countries do not currently recommend self-isolation and testing based on acute loss of smell/taste, they stated.

This study suggests that an overreliance on cough and fever as the main symptoms of COVID-19 may be flawed and that loss of smell needs to be urgently recognized globally as a key symptom of virus.

Meanwhile, the initial reaction to the Coronavirus pandemic in March 2020, including a shutdown of world’s economy for weeks, produced a number of doomsday scenarios from economists.

However, it is possible that those worries were overstated, said economists.

The UCLA Anderson Forecast has gone from classifying the event as a “depression-like crisis” in June to this week revising its forecast to say the economy could have “a better than expected outcome.”

But a lot depends on whether an effective vaccine is found, report said.

Kindly Share This Story